Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry

British Journal of Cancer

Volumn 72, Issue 3, 1995, Pages 543-549

  Feller, N ^a   Kuiper, C M ^a   Lankelma, J ^a   Ruhdal, J K ^a   Scheper, R J ^a   Pinedo, H M ^a   Broxterman, H J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Calcein; Daunorubicin; Multidrug resistance associated protein; P glycoprotein; PSC833; Rhodamine

Indexed keywords

CALCEIN; DAUNORUBICIN; FLUORESCENT DYE; GENISTEIN; GLYCOPROTEIN P; RHODAMINE 123; VALSPODAR; VINCRISTINE;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; COMPARATIVE STUDY; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; FLOW CYTOMETRY; FLUORESCEINS; FLUORESCENT DYES; HUMAN; KB CELLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; RHODAMINE 123; RHODAMINES; SENSITIVITY AND SPECIFICITY; SUPPORT, NON-U.S. GOV'T;

EID: 0029096211     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.371     Document Type: Article

References (37)

1. BRADLEY G, JURANKA PF, AND LING V, (1988). Mechanism of multidrug resistance. Biochim. Biophys. Acta. 948, 87-128.
2. BROXTERMAN HJ, AND PINEDO HM, (1991). Energy metabolism in multidrug resistant tumor cells: a review. J, Cell Pharmacol., 2, 239-247.
3. BROXTERMAN HJ, AND VERSANTVOORT CHM, (1995). Pharmacology of drug transport in multidrug resistant tumor cells. In Alternative Mechanisms of Multidrug Resistance in Cancer. Kellen JA (ed.). pp. 67-80. Birkhauser: Boston.
4. BROXTERMAN HJ, KUIPER CM, EEKMAN CA, FELLER N, SCHUUR-HUIS GJ, PINEDO HM, BAAK JPA, AND LANKELMA J, (1994). Functional detection of multidrug resistant tumour cells using flow cytometry (FC) and laser scan microscopy (LSM). Anal. Cell. Pathol., 6, 214.
5. BURGER H, NOOTER K, ZAMAN GJR, SONNEVELD P, VAN WINGERDEN KE, OOSTRUM RG, AND STOTER G (1994). Expression of the multidrug resistance protein (MRP) in acute and chronic leukemias. Leukemia. 6, 990-997.
6. CENTER MS, (1985). Mechanisms regulating cell resistance to adriamycin. Evidence that drug accumulation in resistant cells is modulated by phosphorylation of a plasma membrane protein. Biochem. Pharmacol., 34, 1471-1476.
7. COLE SPC, BHARDWAJ G, GERLACH JH, MacKIE JE, GRANT CE, ALMQUIST KC, STEWART AJ, KURZ EL, DUNCAN AMV, AND DEELEY RG, (1992). Overexpression of a novel transporter gene in a multidrug resistant human lung cancer cell line. Science. 258, 1650-1654.
8. ENDICOTT JA, AND LING V (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58, 137-171.
9. FLENS MJ, IZQUIERDO MA, SCHEFFER GL, FRITZ JM, MEUER CJLM, SCHEPER RJ, AND ZAMAN GJR, (1994). Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res., 54, 4557-4563.
10. FOJO A, UEDA K, SLAMON DJ, POPLACK DG, GOTTESMAN MM, AND PASTAN I, (1987). Expression of a multidrug resistant gene in human tumors and tissues. Proc. Natl Acad. Sci. USA, 84, 265-269.
11. GRANT CE, VALDIMARSSON G, HIPFNER DR, ALMQUIST KC, COLE SPC, AND DEELEY RG, (1994). Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54, 357-361.
12. GROGAN TM, SPIER CM, SALMON SE, MATZNER M, RYBSKI J, WEINSTEIN RS, SCHEPER RJ, AND DALTON WS, (1993). P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood, 81, 490-495.
13. HIGGINS CF, (1992). ABC transporters from microorganisms to man. Annu. Rev. Cell Biol., 8, 67-113.
14. HOLLÓ Z, HOMOLYA L, DAVIS CM, AND SARKADI B, (1994). Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim. Biophys. Acta. 1191, 384-388.
15. HOMOLYA L, HOLLÓ Z, GERMANN UA, PASTAN I, GOTTESMAN MM, AND SARKADI B, (1993). Fluorescent cellular indicators are extruded by the multidrug resistance protein. J, Biol. Chem., 29, 21493-21496.
16. JEDLITSCHKY G, LEIER I, BUCHHOLZ U, CENTER M, AND KEPP-LER D, (1994). ATP-dependent transport of S-conjugates by the multidrug resistance-associated protein (MRP). Cancer Res., 54, 4833-4836.
17. KUIPER CM, BROXTERMAN HJ, BAAS F, SCHUURHUIS GJ, HAISMA HJ, SCHEFFER GL, LANKELMA J, AND PINEDO HM (1990). Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J, Cell. Pharmacol., 1, 35-41.
18. KUSS BJ, DEELEY RC, COLE SPC, WILLMAN CL, KOPECKY KJ, WOLMAN SR, EYRE HJ, LANE SA, NANCARROW JK, WITH-MORE SA, AND CALLEN DF, (1994). Deletion of the gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet. 343, 1531 -1534.
19. LAMPIDIS TJ, MUNCK JN, KRISHAN A, AND TAPIERO H, (1985). Reversal of resistance to rhodamine in adriamycin-resistant Friend leukemia cells. Cancer Res., 45, 2626-2631.
20. LANKELMA J, SPOELSTRA EC, DEKKER H, AND BROXTERMAN HJ, (1990). Evidence for daunorubicin efflux from multidrug-resistant 2780a0 human ovarium carcinoma cells against a concentration gradient. Biochim. Biophys. Acta. 1055, 217-222.
21. MCGRATH T, LATOUD C, ARNOLD ST, SAFA AR, FELSTED RL, AND CENTER MS, (1989). Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated proteins and levels of mdr gene expression. Biochem. Pharmacol., 38, 3611-3619.
22. MILLER TP, GROGAN TM, DALTON WS, SPIER CM, SCHEPER RJ, AND SALMON SE, (1991). P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J, Clin. Oncol., 9, 17-24.
23. MULDER HS, LANKELMA J, DEKKER H, BROXTERMAN HJ, AND PINEDO HM, (1994). Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug resistance lung-cancer cells. Int. J, Cancer. 59, 275-281.
24. NOOTER K, SONNEVELD P, OOSTRUM R, HERWEIJER H, HAGEN-BEEK T, AND VALERIO D, (1990). Overexpression of the MDR1 gene in blast cells with acute myeloid leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporine. A, Int. J, Cancer. 45, 263-268.
25. ROSS DD, WOOTEN PJ, SRIDHARA R, ORDONEZ JV, LEE EJ, AND SCHIFFER SA, (1993). Enhancement of daunorubicin accumulation. retention and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood, 82, 1288-1299.
26. SCHUURHUIS GJ, BROXTERMAN HJ, DE LANGE JHM, PINEDO HM, VAN HEUNINGEN THM, KUIPER CM, SCHEFFER GL, VAN KALKEN CK, BAAK JPA, AND LANKELMA J, (1991). Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br. J, Cancer, 64, 857-861.
27. SCHUURHUIS GJ, BROXTERMAN HJ, OSSENKOPPELE GJ, BAAK JPA, EEKMAN CA, KUIPER CM, FELLER N, VAN HEIJNINGEN THM, KLUMPER E, PIETERS R, LANKELMA J, AND PINEDO HM, (1995). Functional multidrug resistance phenotype associated with combined overexpression of Pgp MDR\ and MRP together with cytosine-arabinoside sensitivity may predict clinical response in acute myleoid leukemia. Clin. Cancer Res., 1, 81-93.
28. SPOELSTRA EC, WESTERHOFF HV, DEKKER H, AND LANKELMA J, (1992). Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Eur. J, Biochem., 207 567-579.
29. TWENTYMAN PR, RHODES T, AND RAYNER S, (1994). A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur. J, Cancer, 9, 1360-1364.
30. VAN ACKER KL, VAN HOVE LM, AND BOOGAERTS MA (1993). Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies. Cytometry, 14, 736-746.
31. VAN DER VALK P, VAN KALKEN CK, KETELAARS H, BROXTERMAN HJ, SCHEFFER GL, KUIPER CM, TSURUO T, LANKELMA J, MEUER CJLM, PINEDO HM, AND SCHEPER RJ (1990). Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann. Oncol., 1, 56-64.
32. VERSANTVOORT CHM, BROXTERMAN HJ, PINEDO HM, DE VRIES EGE, FELLER N, KUIPER CM, AND LANKELMA J (1992) Energy-dependent processes involved in reduced drug accumulation in multidrug resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res., 52, 17-23.
33. VERSANTVOORT CHM, SCHUURHUIS GJ, PINEDO HM, EEKMAN CA, KUIPER CM, LANKELMA J, AND BROXTERMAN HJ, (1993). Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br. J, Cancer, 68, 939-946.
34. VERSANTVOORT CHM, WITHOFF S, BROXTERMAN HJ, KUIPER CM, SCHEPER RJ, MULDER NH, AND DE VRIES EGE (1995). Resistance associated factors in human small cell lung carcinoma GLC4 sublines with increasing adriamvcin resistance. Int. J, Cancer. 61, 375-380.
35. VERSANTVOORT CHM, BROXTERMAN HJ, BAGRIJ T, SCHEPER RJ, AND TWENTYMAN P, (1995b). Regulation by glutathione of drug transport in multidrug resistant human lung cancer cell lines overexpressing MRP, Br. J, Cancer. 72 (in press).
36. ZAMAN, G.J.R., FLENS MJ, VAN LEUSDEN MR, DE HAAS M, MULDER HS, LANKELMA J, PINEDO HM, SCHEPER RJ, BAAS F, BROXTERMAN HJ, AND BORST P, (1994). The human multidrug resistance-associated protein MRP is a plasma membrane drugefflux pump. Proc. Natl Acad. Sci. USA, 91, 8822-8826.
37. ZULSTRA JG, DE VRIES EGE, AND MULDER NH (1987). Multifactorial drug resistance in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res., 47, 1780-1784.